In this edition of Market Checkup, health-care analysts David Williamson and Max Macaluso discuss today's biggest health-care news, including Amgen's multibillion-dollar acquisition of oncology specialist Onyx Pharmaceuticals, Rigel Pharmaceuticals' latest clinical trial disappointment, new allegations of a big pharma's misconduct in China, and a new opportunity in Eli Lilly's animal health division.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
The Motley Fool's health-care show "Market Checkup" for Aug. 26, 2013.
David Williamson owns shares of Pfizer. Max Macaluso, Ph.D. owns shares of Celgene. The Motley Fool recommends Celgene. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Related Articles
Billionaire Stanley Druckenmiller Loaded Up on These 3 Stocks. Are They Buys?
3 Reasons to Buy Eli Lilly Stock Like There's No Tomorrow
3 High-Yielding Dividend Stocks to Buy for the Long Haul
Why Did Hims and Hers Stock Crash on Monday?
Novo Nordisk Has Ended Its Wegovy Deal With Hims & Hers: Here's What Investors Need to Know
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.